Eurofarma

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

Retrieved on: 
Thursday, August 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IBM, BlackRock, Cancer, NK, Cell, KLRG1, Patient, Malignancy, Pharmaceutical industry, Vaccine, Eurofarma

Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the successful close of an oversubscribed $155 million Series B financing co-led by Redmile Group and Bain Capital Life Sciences.

Key Points: 
  • Abcuro, Inc. , a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the successful close of an oversubscribed $155 million Series B financing co-led by Redmile Group and Bain Capital Life Sciences.
  • “Support from such a strong group of investors will allow us to complete our development programs in diseases where there are few to no treatment options available,” said Alex Martin, Chief Executive Officer of Abcuro.
  • “We are very motivated by the patients we serve and are excited by the clinical data we’ve seen to date.
  • “IBM, like other autoimmune diseases, is progressive and devastating for patients.

Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public

Retrieved on: 
Wednesday, March 29, 2023
Online, Social responsibility, Artesunate, Idiopathic pulmonary fibrosis, Rituximab, Fosun Pharma, MPP, COVID-19, Family, Spasm, Multimedia, Corporate social responsibility, Axicabtagene ciloleucel, CSR, Medicines Patent Pool, Psoriasis, The Bund Finance Center, Occupational Safety and Health Act 1994, MSCI, Health Level Seven International, Patient, Annual report, Adalimumab, Developed country, EHS, Trastuzumab, Diagnosis, ESG, R, Rare, Immunodeficiency, Health, Pulmonary hypertension, Environment, Air pollution, RMB, Safety, Malaria, Pharmaceutical industry, Azvudine, Eurofarma, Organon

As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported.

Key Points: 
  • As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported.
  • Through its strengths, Fosun Pharma is also helping to solve drug accessibility problems in developing countries and underdeveloped areas.
  • Moreover, Fosun Pharma owns industry-leading capability in in&out licensing and internationalization, maximizing the value of each innovative product.
  • Furthermore, Fosun Pharma is continually striving for excellence, improving its product quality and medical services, and launched Fosun Pharma Operation Excellence (FOPEX) in 2016.